These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 23958570

  • 1. Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.
    Lezzar A, Ayad F, Dahaoui A, Salah-Mansour A, Berrouiguet AY.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S37-44. PubMed ID: 23958570
    [Abstract] [Full Text] [Related]

  • 2. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
    Malek R, Arbouche Z, Bachaoui M, Zinai S, Dahaoui A, Senoussaoui S, Salah-Mansour A.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
    [Abstract] [Full Text] [Related]

  • 3. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ.
    Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
    [Abstract] [Full Text] [Related]

  • 4. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA, Yu-Gan S, Jain AB, Sobrepena LM, Racho VA.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [Abstract] [Full Text] [Related]

  • 5. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
    Latif ZA, Pathan MF, Siddiqui MN, Sobhan MJ, Rahman MM, Ashrafuzzaman SM.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
    [Abstract] [Full Text] [Related]

  • 6. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
    Lim-Abrahan MA, Jain AB, Bebakar WM, Seah D, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
    [Abstract] [Full Text] [Related]

  • 7. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
    Soewondo P, Lindarto D, Wibisono S, Renaldi O, Dalem-Pemayun TG.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
    [Abstract] [Full Text] [Related]

  • 8. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P, Pramono RB, Langi YA, Soetedjo NN, Kshanti IA.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S54-9. PubMed ID: 23647720
    [Abstract] [Full Text] [Related]

  • 9. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [Abstract] [Full Text] [Related]

  • 10. Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study.
    Malek R, Arbouche Z, Dahaoui A, Bachaoui M.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S15-26. PubMed ID: 23958568
    [Abstract] [Full Text] [Related]

  • 11. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S, Sothiratnam R, Sari R, Andersen H, Hiort LC, Rao P.
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [Abstract] [Full Text] [Related]

  • 12. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
    Hassan MI, Aamir AH, Miyan Z, Siddiqui LA, Qureshi MS, Shaikh MZ.
    J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
    [Abstract] [Full Text] [Related]

  • 13. Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results.
    Nobels F, D'Hooge D, Crenier L.
    Curr Med Res Opin; 2012 Jun; 28(6):1017-26. PubMed ID: 22612579
    [Abstract] [Full Text] [Related]

  • 14. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK, Schmüser C, Askonen K, Saukkonen T.
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [Abstract] [Full Text] [Related]

  • 15. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
    Guo L, Chen L, Chang B, Yang L, Liu Y, Feng B.
    Diabetes Obes Metab; 2018 Dec; 20(12):2740-2747. PubMed ID: 29961975
    [Abstract] [Full Text] [Related]

  • 16. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 17. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, Niskanen LK, BOOST: Intensify Premix I Investigators.
    Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
    [Abstract] [Full Text] [Related]

  • 18. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P, Wojciechowski P, Siejka S, Małecki P, Hak L, Malecki MT.
    Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
    [Abstract] [Full Text] [Related]

  • 19. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, Donnet JP, Endahl L, Skjøth TV, Vaag A.
    Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
    [Abstract] [Full Text] [Related]

  • 20. Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.
    Belhadj M, Dahaoui A, Jamoussi H, Farouqi A.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S4-14. PubMed ID: 23958571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.